179 related articles for article (PubMed ID: 22252846)
1. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Toledo Perdomo K; Navarro Cabello MD; Pérez Sáez MJ; Ramos Pérez MJ; Agüera Morales ML; Aljama García P
J Nephrol; 2012; 25(5):839-42. PubMed ID: 22252846
[TBL] [Abstract][Full Text] [Related]
2. Akinetic mutism induced by tacrolimus.
Sierra-Hidalgo F; Martínez-Salio A; Moreno-García S; de Pablo-Fernández E; Correas-Callero E; Ruiz-Morales J
Clin Neuropharmacol; 2009; 32(5):293-4. PubMed ID: 19820432
[TBL] [Abstract][Full Text] [Related]
3. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report.
Prates LC; Rigatto SZ; Lutaif AC; Oliveira LC; Pereira LM; Passerotti LC; Belangero VM
Transplant Proc; 2012 Oct; 44(8):2510-1. PubMed ID: 23026634
[TBL] [Abstract][Full Text] [Related]
4. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Wu Q; Marescaux C; Wolff V; Jeung MY; Kessler R; Lauer V; Chen Y
Eur Neurol; 2010; 64(3):169-77. PubMed ID: 20699617
[TBL] [Abstract][Full Text] [Related]
6. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
7. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
8. Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Hayes D; Adler B; Turner TL; Mansour HM
Pediatr Neurol; 2014 Mar; 50(3):272-5. PubMed ID: 24405697
[TBL] [Abstract][Full Text] [Related]
9. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation.
Vearrier D; Simpson SE; Greenberg MI
Am J Ther; 2011 Nov; 18(6):e274-6. PubMed ID: 20535006
[TBL] [Abstract][Full Text] [Related]
10. Catatonia as a manifestation of tacrolimus-induced neurotoxicity in organ transplant patients: a case series.
Chopra A; Das P; Rai A; Kuppuswamy PS; Li X; Huston J; Philbrick K; Sola C
Gen Hosp Psychiatry; 2012; 34(2):209.e9-11. PubMed ID: 21937118
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
12. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
13. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
15. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
16. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
[TBL] [Abstract][Full Text] [Related]
17. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Langer RM; Hené R; Vitko S; Christiaans M; Tedesco-Silva H; Ciechanowski K; Cassuto E; Rostaing L; Vilatoba M; Machein U; Ulbricht B; Junge G; Dong G; Pascual J
Transpl Int; 2012 May; 25(5):592-602. PubMed ID: 22471345
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
